Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

A Burger

Showing results (1031-1040 of 1,155) with videos related to

Pageof 116
Sort By:
Blood|April 5, 2017
Impact of ibrutinib dose adherence on therapeutic efficacy in patients with previously treated CLL/SLLPaul M Barr, Jennifer R Brown, Peter Hillmen, et al.
Gynecologic Oncology|August 16, 2017
An evaluation of progression free survival and overall survival of ovarian cancer patients with clear cell carcinoma versus serous carcinoma treated with platinum therapy: An NRG Oncology/Gynecologic Oncology Group experienceKate E Oliver, William E Brady, Michael Birrer, et al.
The New England Journal of Medicine|June 21, 2013
Targeting BTK with ibrutinib in relapsed chronic lymphocytic leukemiaJohn C Byrd, Richard R Furman, Steven E Coutre, et al.
Plos Pathogens|August 25, 2021
Antibody responses induced by SHIV infection are more focused than those induced by soluble native HIV-1 envelope trimers in non-human primatesJelle van Schooten, Marlies M van Haaren, Hui Li, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 11, 2020
Predictive Blood-Based Biomarkers in Patients with Epithelial Ovarian Cancer Treated with Carboplatin and Paclitaxel with or without Bevacizumab: Results from GOG-0218Angeles Alvarez Secord, Kirsten Bell Burdett, Kouros Owzar, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 16, 2013
PRECEDENT: a randomized phase II trial comparing vintafolide (EC145) and pegylated liposomal doxorubicin (PLD) in combination versus PLD alone in patients with platinum-resistant ovarian cancerR Wendel Naumann, Robert L Coleman, Robert A Burger, et al.
The Lancet. Oncology|December 17, 2013
Ibrutinib as initial therapy for elderly patients with chronic lymphocytic leukaemia or small lymphocytic lymphoma: an open-label, multicentre, phase 1b/2 trialSusan O'Brien, Richard R Furman, Steven E Coutre, et al.
Proceedings of the National Academy of Sciences of the United States of America|May 11, 2016
Ancient and modern DNA reveal dynamics of domestication and cross-continental dispersal of the dromedaryFaisal Almathen, Pauline Charruau, Elmira Mohandesan, et al.
NPJ Vaccines|February 10, 2021
Immunofocusing and enhancing autologous Tier-2 HIV-1 neutralization by displaying Env trimers on two-component protein nanoparticlesPhilip J M Brouwer, Aleksandar Antanasijevic, Marlon de Gast, et al.
Gynecologic Oncology|February 7, 2024
Health-related quality of life in patients with newly diagnosed advanced ovarian cancer treated with niraparib vs placebo: Results from the phase 3 randomized PRIMA/ENGOT-OV26/GOG-3012 trialBhavana Pothuri, Sileny Han, Dana M Chase, et al.
Pageof 116

Showing results (1031-1040 of 1,155) with videos related to

Sort By:
Pageof 116
Blood|April 5, 2017
Impact of ibrutinib dose adherence on therapeutic efficacy in patients with previously treated CLL/SLLPaul M Barr, Jennifer R Brown, Peter Hillmen, et al.
Gynecologic Oncology|August 16, 2017
An evaluation of progression free survival and overall survival of ovarian cancer patients with clear cell carcinoma versus serous carcinoma treated with platinum therapy: An NRG Oncology/Gynecologic Oncology Group experienceKate E Oliver, William E Brady, Michael Birrer, et al.
The New England Journal of Medicine|June 21, 2013
Targeting BTK with ibrutinib in relapsed chronic lymphocytic leukemiaJohn C Byrd, Richard R Furman, Steven E Coutre, et al.
Plos Pathogens|August 25, 2021
Antibody responses induced by SHIV infection are more focused than those induced by soluble native HIV-1 envelope trimers in non-human primatesJelle van Schooten, Marlies M van Haaren, Hui Li, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 11, 2020
Predictive Blood-Based Biomarkers in Patients with Epithelial Ovarian Cancer Treated with Carboplatin and Paclitaxel with or without Bevacizumab: Results from GOG-0218Angeles Alvarez Secord, Kirsten Bell Burdett, Kouros Owzar, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 16, 2013
PRECEDENT: a randomized phase II trial comparing vintafolide (EC145) and pegylated liposomal doxorubicin (PLD) in combination versus PLD alone in patients with platinum-resistant ovarian cancerR Wendel Naumann, Robert L Coleman, Robert A Burger, et al.
The Lancet. Oncology|December 17, 2013
Ibrutinib as initial therapy for elderly patients with chronic lymphocytic leukaemia or small lymphocytic lymphoma: an open-label, multicentre, phase 1b/2 trialSusan O'Brien, Richard R Furman, Steven E Coutre, et al.
Proceedings of the National Academy of Sciences of the United States of America|May 11, 2016
Ancient and modern DNA reveal dynamics of domestication and cross-continental dispersal of the dromedaryFaisal Almathen, Pauline Charruau, Elmira Mohandesan, et al.
NPJ Vaccines|February 10, 2021
Immunofocusing and enhancing autologous Tier-2 HIV-1 neutralization by displaying Env trimers on two-component protein nanoparticlesPhilip J M Brouwer, Aleksandar Antanasijevic, Marlon de Gast, et al.
Gynecologic Oncology|February 7, 2024
Health-related quality of life in patients with newly diagnosed advanced ovarian cancer treated with niraparib vs placebo: Results from the phase 3 randomized PRIMA/ENGOT-OV26/GOG-3012 trialBhavana Pothuri, Sileny Han, Dana M Chase, et al.
Pageof 116